INTRODUCTION
Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy typically occurring after respiratory and gastrointestinal infections and is usually caused by viral and bacterial infections.
1 GBS is a rare complication related to hematopoietic stem cell transplantation (HSCT). 2 Dengue is a highly prevalent arboviral disease in the tropics caused by viruses belonging to the Flaviviridae family. The dengue virus (DENV) has four serotypes, DENV 1-4.
In Brazil, since its re-introduction, dengue epidemics have been reported annually, with cocirculation of different serotypes over time. Currently, the World Health Organization estimates that approximately 2.5 billion people are living in endemic areas, and 390 million dengue cases occur per year. 3, 4 The incidence of neurological complications after DENV infection ranges from 1%-25%, with the most common presentations including encephalopathy, GBS, acute motor weakness, seizures, neuritis, hypokalemic paralysis, and pyramidal tract signs. 5, 6 Accepted Article
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Following a diagnosis of GBS, the patient received 2 g/kg intravenous immunoglobulin (IVIg) (Tegeline®; LFB Biomedicaments, Lille, France), and her neurological symptoms consequently improved. She was discharged after 1 week, with partial recovery of strength, sensitivity, and reflexes, and total recovery of paresthesia. A week later, because of worsening of the neurological symptoms and respiratory insufficiency that required mechanical ventilation, she underwent plasmapheresis and received another cycle of IVIg (total, 3 g/kg). The patient slowly recovered and, 4 months after the initial diagnosis, the patient did not present any neurological sequelae.
Blood and CSF samples previously collected on post-transplant days +92, +100, and +296 were submitted for laboratory diagnosis of DENV and ZIKV infections, as the patient's hometown was experiencing a double epidemic of ZIKV and DENV ( Figure 1A ). The serum sample from day +92 post HSCT was negative for the presence of DENV NS1 antigen (PanBio ® , Alere, USA), and reverse transcription-PCR was negative for DENV 10 and ZIKV 11 nucleic acids. Molecular generic flavivirus detection was also negative. 12 Regarding flavivirus
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against the microorganism may react with antigens on the nerve tissues or may cause direct damage via viral neurotropism. 19 The first hypothesis became more likely after Cao-Lormeau et al. 1 demonstrated a temporal association between peaks in the incidence of ZIKV infections and GBS, and Siu et al. 19 described an acute ZIKV infection concurrent with the onset of GBS in a patient experiencing a secondary flavivirus infection. Furthermore, this hypothesis is supported by the demonstration of serological cross-reactivity between infections caused by viruses of the Flaviviridae family, such as DENV, YFV, West Nile, and Japanese encephalitis viruses. 20 Recently, reports have demonstrated that ZIKV infection, in individuals with a history of a previous flavivirus infection (or vaccination), such as DENV and YFV, may result in a boost in the pre-existing antibodies, which could enhance the infectivity of ZIKV and the severity of the infection. [21] [22] [23] The serum sample of the bone marrow donor contained IgG antibodies against DENV, and if the patient was recently infected by ZIKV, the previous DENV antibodies from the donor would have enhanced the severity of the ZIKV infection, leading to GBS. In one previous study, patients with GBS after ZIKV infection had atypically low levels of anti-ganglioside antibodies compared to patients with GBS caused by other etiologies, suggesting that ZIKV may induce GBS by different mechanisms.
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In the case reported here, all molecular tests for identifying acute flavivirus infection were negative. However, we could not exclude a recent ZIKV infection because the viremia during the acute phase of the disease is usually low and transient. 19, 24 Notably, the patient had no classical symptoms related to the acute phase of infection by both viruses. Regarding ZIKV infection cases, more studies are needed to determine the dynamics of viral clearance and the kinetics of the immune response, as well as the risk of chronicity, reactivation, and reinfection by this pathogen among immunosuppressed patients.
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Concerning the serological profile, typically, in the course of flavivirus infections, IgM is detected within a few days after the onset of symptoms and may persist up to 3 months.
IgG antibodies appear a few days later and can persist for years. 19 Although the patient described in this study lives in a region with a high prevalence of both DENV and ZIKV, she had no known history of previous DENV infection, but a YFV vaccination in 2006.
It is well documented that serological assays to detect DENV and ZIKV infection may not be able to discriminate between these infections, owing to the extended crossreactivity. This cross-reactivity is probably caused by the high amino acid sequence homology of the envelope E protein with flaviviruses belonging to the same serocomplex.
25
To circumvent this problem and discriminate ZIKV and DENV infections, we performed neutralization assays for both viruses ( Figure 1B ).
The results of serological tests with samples collected on days +92, +100, and +296
showed antibodies against both DENV and ZIKV. The anti-ZIKV IgM titers had a four-fold increase in the paired samples, while anti-DENV IgM titers were constant in the first two samples and undetectable on day +296. These findings suggest that the patient had a recent ZIKV infection. Nevertheless, we cannot exclude the possibility that the patient was coinfected by DENV and ZIKV during the 17-day stay in her hometown, because both viruses co-circulate in the region. However, it is also possible that the pre-existing donor antibodies to flaviviruses such as DENV would act as an enhancement factor, leading to the severe clinical picture of GBS. Reinforcing this hypothesis, two subsequent analyses showed 100% chimerism in the patient samples, i.e., all receipient hematopoietic cells were from the donor.
Accepted Article
This article is protected by copyright. All rights reserved. 
